Ipsen (IPSEF) Research & Development: $876 Mil (TTM As of Dec. 2025)


IPSEF Ipsen SA IPSEF
95 GF Score
Price $113.13
GF Value $92.81
! 7 Warning Signs
View Full Analysis

What is Ipsen Research & Development?

Ipsen IPSEF 95 Research & Development is $876 Mil as of Dec. 2025. GuruFocus rates IPSEF with a GF Score™ of 95/100 and a GF Value™ of $92.81. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ipsen's Research & Development for the six months ended in Dec. 2025 was $456 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $876 Mil.

Ipsen  (OTCPK:IPSEF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ipsen Research & Development Related Terms

Ipsen Research & Development Historical Data

* Premium members only.

The historical data trend for Ipsen's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipsen Research & Development Chart

Ipsen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 479.55 471.72 675.35 718.95 882.90

Ipsen Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 358.89 348.12 380.31 420.88 455.62
IPSEF
95GF Score
Ipsen SA IPSEF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ipsen Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $876 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $876 Mil mean?
Ipsen (IPSEF) has a Research & Development of $876 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Ipsen and its competitors.
Is Ipsen's Research & Development too high?
Ipsen's current Research & Development is $876 Mil. Overall, Ipsen has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Ipsen's Research & Development compare to ZTS and UTHR?
Ipsen's Research & Development of $876 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ipsen and its competitors. Ipsen's current Research & Development is $876 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Ipsen (IPSEF) has a current Research & Development of $876 Mil. The stock's GF Value™ is $92.81, compared to a current price of $113.13 — trading 21.9% above its estimated fair value. The current Research & Development is $876 Mil. Ipsen's overall GF Score™ is 95/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ipsen (IPSEF), the current Research & Development is $876 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipsen (IPSEF) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of $113.13 is trading 21.9% above its estimated GF Value™ of $92.81.

Key valuation signals for IPSEF:

  • Research & Development: $876 Mil
  • GF Value™: $92.81 vs. price of $113.13 (21.9% above fair value)
  • GF Score™: 95/100 with 7 warning signs

No single metric tells the full story. See the IPSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
95GF Score

Get the complete analysis for IPSEF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$113.13
Price
$92.81
GF Value